Risuteganib shows potential in dry AMD

SAN FRANCISCO — Risuteganib showed potential for the treatment of intermediate dry age-related macular degeneration, according to study results presented at Retina Subspecialty Day prior to the American Academy of Ophthalmology annual meeting.
“The pathogenesis of dry AMD is not well established; however, there’s toxicity of stress that causes photoreceptor and RPE-degeneration and incites inflammation – all these lead to a potential loss of function,” David S. Boyer, MD, of the Retina-Vitreous Associates Medical Group, California, said during the presentation. “This

Full Story →